SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

WTX-330

HOWL·Werewolf Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Unknown/unverified, no Phase 2/3 industry-sponsored records for WTX-330 exist in SecBot's ingested ClinicalTrials.gov d
Time to market
Unknown, clinical stage could not be verified this session (no web access, no SecBot FDA/trial records for WTX-330).
Why 2/10
No hard, dated catalyst (PDUFA, pivotal readout, or regulatory decision) for WTX-330 could be identified this session: external web research was unavailable (repeated search-tool timeouts, then the monthly MCP quota was exhausted), and SecBot's ingested FDA/ClinicalTrials.gov data contain zero WTX-330 records, with no verifiable binary event, the score sits at the low end of the rubric.
Actionable Insight NEUTRAL

Before any position, verify WTX-330's actual clinical stage and next data-readout date from Werewolf's IR site and press releases, this session's tools could not retrieve them. Note the setup: a ~$0.36 micro-cap where the single-analyst $7 target implies massive upside but where zero SecBot-ingested Phase 2/3 trial records exist for this drug, so near-term moves are likely binary, event-driven, and unverifiable here.

Price Chart

Loading chart...

Executive Summary

WTX-330 is a pipeline candidate at Werewolf Therapeutics. This session's external web research could NOT be completed: every search_web call timed out or hit the exhausted monthly quota, so no third-party coverage, trial results, or regulatory dates for WTX-330 could be retrieved, and SecBot's local FDA actions/catalysts/trials tables return no WTX-330 entries. Company-level facts are grounded in tool results: the stock last quoted near $0.36 (2026-08-03), the latest analyst snapshot shows 8 Buy/Strong-Buy vs 2 Hold and 0 Sell ratings, a single-analyst price-target snapshot sits at $7 (implied upside ~1825% vs the snapshot's $0.3531 price), and insiders (MPM-affiliated director via a 10b5-1 plan) have been selling small lots. Because the drug's actual phase and next catalyst are unverifiable from this session's tools, the read is neutral.

How It Works

Not verified this session, no mechanism description could be retrieved from any tool result. WTX-330 is a pipeline molecule at an engineered-cytokine immuno-oncology company, but specific claims about how it works would be ungrounded here.

The Two-Sided Case

▲ Bull Case3
Latest analyst snapshot is net positive: 8 Buy/Strong-Buy ratings vs 2 Hold and 0 Sell for HOWL.
Price-target snapshot shows a $7 mean target vs a $0.3531 stored current price, the tool's impliedUpside field reads 1825.2% (single analyst in that snapshot; treat as thin).
Micro-cap quote (~$0.36) means even modest positive early clinical news on any lead candidate can produce outsized percentage moves.
▼ Bear Case3
No WTX-330 clinical records exist in SecBot's ingested Phase 2/3 ClinicalTrials.gov or FDA datasets, and no external coverage could be retrieved, phase/status is unverifiable, and an early-stage program is likely years from commercialization with high failure risk.
Insider selling is ongoing: director (MPM-affiliated) 10b5-1-plan sales of ~$33k (2026-07-07), ~$11k (2026-07-06) and ~$47k (2026-06-29) gross per Form 4s, pre-planned, but adds supply overhang at a ~$0.36 quote.
Deep-micro-cap financing risk: funding early clinical trials typically requires dilution at these price levels, and the gap between the single-analyst $7 target and the ~$0.36 quote illustrates binary, event-driven volatility.

Upcoming Catalysts

  • No verified dated catalysts, external research unavailable this session. Watch for: Werewolf press releases on WTX-330 clinical data (unverified), quarterly results/financing news, and any 8-K disclosures; re-run web research after 2026-09-01 when the search quota resets.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Werewolf Therapeutics, Inc. 8-K HOWL ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov